Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinomaRobin Park, Christine H. Chung, Xiaofei Song et al.|Oral Oncology|2024Cited by 5
Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck CancerRitu Chaudhary, Christine H. Chung, Graydon Moorhead et al.|Clinical Cancer Research|2025Cited by 3
Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N).Robin Park, Christine H. Chung, F. Rind et al.|Journal of Clinical Oncology|2023Cited by 1
Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).Christine H. Chung, Aik Choon Tan, Graydon Moorhead et al.|Journal of Clinical Oncology|2023Cited by 1
Data from Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck CancerRitu Chaudhary, Christine H. Chung, Graydon Moorhead et al.|Unknown|2026Cited by 0